XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.33

-8.6%

Jan 16 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Bluegreen who wrote (12393)	12/5/1999 10:36:00 AM
From: aknahow	Read Replies (1) of 17367

Bluegreen, I admit I get irritated with Yahoo posters that try to make XOMA look like a company that has always failed. Even Cacaito, overcomes his bitterness, to admit that XOMA has done important things a a MAB company. Each time I read about Rituxan I remember that XOMA played a key part. I applauded their sale of the royalties so can complain about that decision. But if people think that those in other companies are not aware of the contribution made by XOMA, they are wrong. Genentechs 1995 annual report carried no fewer than 8 favorable references to XOMA. Rituxan is one of the few MABs to enjoy such great success. <<<<<<"The diverse data presented at ASH will provide insights into the safety and broad potential applicability of Rituxan to target various CD20-positive B-cell malignant and non-malignant hematological disorders," said Gwen Fyfe, M.D., Genentech's senior director of Oncology. ">>>>>>>>> From a Dec. 4 DNA press release.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next